Krystal Biotech Analyst Ratings
Krystal Biotech Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 53.61% | Goldman Sachs | → $160 | Initiates Coverage On | → Buy |
| 11/07/2023 | 53.61% | Cantor Fitzgerald | → $160 | Reiterates | Overweight → Overweight |
| 10/24/2023 | 53.61% | Cantor Fitzgerald | → $160 | Initiates Coverage On | → Overweight |
| 10/12/2023 | 53.61% | Citigroup | → $160 | Initiates Coverage On | → Buy |
| 09/07/2023 | 47.85% | Berenberg | → $154 | Initiates Coverage On | → Buy |
| 08/08/2023 | 46.89% | Chardan Capital | $148 → $153 | Maintains | Buy |
| 08/07/2023 | 33.45% | HC Wainwright & Co. | → $139 | Reiterates | Buy → Buy |
| 07/27/2023 | 33.45% | HC Wainwright & Co. | → $139 | Reiterates | Buy → Buy |
| 07/03/2023 | 33.45% | HC Wainwright & Co. | → $139 | Reiterates | → Buy |
| 05/25/2023 | 34.41% | B of A Securities | $118 → $140 | Maintains | Buy |
| 05/24/2023 | 39.21% | Stifel | $102 → $145 | Maintains | Buy |
| 05/22/2023 | 24.81% | Guggenheim | $101 → $130 | Maintains | Buy |
| 05/22/2023 | 48.81% | Goldman Sachs | $135 → $155 | Maintains | Buy |
| 05/22/2023 | 42.09% | Chardan Capital | $133 → $148 | Maintains | Buy |
| 05/22/2023 | 33.45% | HC Wainwright & Co. | $119 → $139 | Maintains | Buy |
| 05/22/2023 | 13.29% | B of A Securities | $105 → $118 | Maintains | Buy |
| 05/07/2023 | 29.61% | Goldman Sachs | → $135 | Maintains | Buy |
| 04/18/2023 | -2.07% | Stifel | → $102 | Initiates Coverage On | → Buy |
| 02/28/2023 | -3.03% | Guggenheim | → $101 | Reiterates | → Buy |
| 02/28/2023 | 14.25% | HC Wainwright & Co. | → $119 | Reiterates | → Buy |
| 02/28/2023 | 19.05% | Goldman Sachs | $79 → $124 | Upgrades | Neutral → Buy |
| 02/28/2023 | 27.69% | Chardan Capital | → $133 | Reiterates | → Buy |
| 11/08/2022 | 27.69% | Chardan Capital | $130 → $133 | Maintains | Buy |
| 11/07/2022 | -24.16% | Goldman Sachs | $74 → $79 | Maintains | Neutral |
| 11/07/2022 | 14.25% | HC Wainwright & Co. | $107 → $119 | Maintains | Buy |
| 08/25/2022 | -28.96% | Goldman Sachs | → $74 | Downgrades | Buy → Neutral |
| 08/09/2022 | 24.81% | Chardan Capital | $137 → $130 | Maintains | Buy |
| 08/08/2022 | -28.96% | Goldman Sachs | $78 → $74 | Maintains | Buy |
| 05/24/2022 | -25.12% | Goldman Sachs | $91 → $78 | Maintains | Buy |
| 03/01/2022 | -10.71% | Goldman Sachs | $125 → $93 | Maintains | Buy |
| 02/28/2022 | 2.73% | HC Wainwright & Co. | $124 → $107 | Maintains | Buy |
| 01/18/2022 | 5.61% | B of A Securities | → $110 | Initiates Coverage On | → Buy |
| 11/30/2021 | 19.05% | HC Wainwright & Co. | $103 → $124 | Maintains | Buy |
| 11/29/2021 | 20.01% | Goldman Sachs | $85 → $125 | Maintains | Buy |
| 11/29/2021 | 19.05% | HC Wainwright & Co. | $103 → $124 | Maintains | Buy |
| 08/09/2021 | -16.47% | Goldman Sachs | $90 → $87 | Maintains | Buy |
| 07/20/2021 | -13.59% | Goldman Sachs | $73 → $90 | Upgrades | Neutral → Buy |
| 05/10/2021 | -29.92% | Goldman Sachs | $85 → $73 | Maintains | Neutral |
| 03/01/2021 | -1.11% | HC Wainwright & Co. | $84 → $103 | Maintains | Buy |
| 02/09/2021 | -6.87% | JonesTrading | → $97 | Initiates Coverage On | → Buy |
| 01/08/2021 | -19.35% | HC Wainwright & Co. | $68 → $84 | Maintains | Buy |
| 09/18/2020 | -3.99% | B. Riley Securities | → $100 | Initiates Coverage On | → Buy |
| 08/19/2020 | 10.41% | Chardan Capital | $100 → $115 | Maintains | Buy |
| 03/10/2020 | -34.72% | HC Wainwright & Co. | $59 → $68 | Maintains | Buy |
| 09/24/2019 | -42.4% | Goldman Sachs | → $60 | Initiates Coverage On | → Neutral |
| 08/06/2019 | -43.36% | HC Wainwright & Co. | $56 → $59 | Maintains | Buy |
| 06/25/2019 | -29.92% | Guggenheim | $48 → $73 | Reiterates | → Buy |
| 05/30/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 12/12/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/20/2023 | 53.61% | 高盛 | → 160 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/07/2023 | 53.61% | 坎託·菲茨傑拉德 | → 160 美元 | 重申 | 超重 → 超重 |
| 2023 年 10 月 24 日 | 53.61% | 坎託·菲茨傑拉德 | → 160 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2023 年 12 月 10 日 | 53.61% | 花旗集團 | → 160 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/07/2023 | 47.85% | 貝倫貝格 | → 154 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/08/2023 | 46.89% | 查丹資本 | 148 美元 → 153 美元 | 維護 | 買 |
| 08/07/2023 | 33.45% | HC Wainwright & Co. | → 139 美元 | 重申 | 購買 → 購買 |
| 07/27/2023 | 33.45% | HC Wainwright & Co. | → 139 美元 | 重申 | 購買 → 購買 |
| 07/03/2023 | 33.45% | HC Wainwright & Co. | → 139 美元 | 重申 | → 購買 |
| 05/25/2023 | 34.41% | B of A 類證券 | 118 美元 → 140 美元 | 維護 | 買 |
| 05/24/2023 | 39.21% | Stifel | 102 美元 → 145 美元 | 維護 | 買 |
| 05/22/2023 | 24.81% | 古根海姆 | 101 美元 → 130 美元 | 維護 | 買 |
| 05/22/2023 | 48.81% | 高盛 | 135 美元 → 155 美元 | 維護 | 買 |
| 05/22/2023 | 42.09% | 查丹資本 | 133 美元 → 148 美元 | 維護 | 買 |
| 05/22/2023 | 33.45% | HC Wainwright & Co. | 119 美元 → 139 美元 | 維護 | 買 |
| 05/22/2023 | 13.29% | B of A 類證券 | 105 美元 → 118 美元 | 維護 | 買 |
| 05/07/2023 | 29.61% | 高盛 | → 135 美元 | 維護 | 買 |
| 04/18/2023 | -2.07% | Stifel | → 102 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 02/28/2023 | -3.03% | 古根海姆 | → 101 美元 | 重申 | → 購買 |
| 02/28/2023 | 14.25% | HC Wainwright & Co. | → 119 美元 | 重申 | → 購買 |
| 02/28/2023 | 19.05% | 高盛 | 79 美元 → 124 美元 | 升級 | 中性 → 買入 |
| 02/28/2023 | 27.69% | 查丹資本 | → 133 美元 | 重申 | → 購買 |
| 2022 年 8 月 11 日 | 27.69% | 查丹資本 | 130 美元 → 133 美元 | 維護 | 買 |
| 2022 年 7 月 11 日 | -24.16% | 高盛 | 74 美元 → 79 美元 | 維護 | 中立 |
| 2022 年 7 月 11 日 | 14.25% | HC Wainwright & Co. | 107 美元 → 119 美元 | 維護 | 買 |
| 08/25/2022 | -28.96% | 高盛 | → 74 美元 | 降級 | 買入 → 中性 |
| 08/09/2022 | 24.81% | 查丹資本 | 137 美元 → 130 美元 | 維護 | 買 |
| 08/08/2022 | -28.96% | 高盛 | 78 美元 → 74 美元 | 維護 | 買 |
| 2022 年 5 月 24 日 | -25.12% | 高盛 | 91 美元 → 78 美元 | 維護 | 買 |
| 03/01/2022 | -10.71% | 高盛 | 125 美元 → 93 美元 | 維護 | 買 |
| 02/28/2022 | 2.73% | HC Wainwright & Co. | 124 美元 → 107 美元 | 維護 | 買 |
| 01/18/2022 | 5.61% | B of A 類證券 | → 110 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 11 月 30 日 | 19.05% | HC Wainwright & Co. | 103 美元 → 124 美元 | 維護 | 買 |
| 11/29/2021 | 20.01% | 高盛 | 85 美元 → 125 美元 | 維護 | 買 |
| 11/29/2021 | 19.05% | HC Wainwright & Co. | 103 美元 → 124 美元 | 維護 | 買 |
| 2021 年 9 月 8 日 | -16.47% | 高盛 | 90 美元 → 87 美元 | 維護 | 買 |
| 2021 年 7 月 20 日 | -13.59% | 高盛 | 73 美元 → 90 美元 | 升級 | 中性 → 買入 |
| 2021 年 10 月 5 日 | -29.92% | 高盛 | 85 美元 → 73 美元 | 維護 | 中立 |
| 2021 年 1 月 3 日 | -1.11% | HC Wainwright & Co. | 84 美元 → 103 美元 | 維護 | 買 |
| 02/09/2021 | -6.87% | JonesTrading | → 97 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 01/08/2021 | -19.35% | HC Wainwright & Co. | 68 美元 → 84 美元 | 維護 | 買 |
| 09/18/2020 | -3.99% | B. 萊利證券 | → 100 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 8 月 19 日 | 10.41% | 查丹資本 | 100 美元 → 115 美元 | 維護 | 買 |
| 2020 年 10 月 3 日 | -34.72% | HC Wainwright & Co. | 59 美元 → 68 美元 | 維護 | 買 |
| 2019 年 9 月 24 日 | -42.4% | 高盛 | → 60 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 08/06/2019 | -43.36% | HC Wainwright & Co. | 56 美元 → 59 美元 | 維護 | 買 |
| 06/25/2019 | -29.92% | 古根海姆 | 48 美元 → 73 美元 | 重申 | → 購買 |
| 2019 年 5 月 30 日 | — | 古根海姆 | 啓動覆蓋範圍開啓 | → 購買 | |
| 12/12/2018 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Krystal Biotech (KRYS)?
Krystal Biotech（KRYS）的目標價格是多少？
The latest price target for Krystal Biotech (NASDAQ: KRYS) was reported by Goldman Sachs on November 20, 2023. The analyst firm set a price target for $160.00 expecting KRYS to rise to within 12 months (a possible 53.61% upside). 22 analyst firms have reported ratings in the last year.
高盛於2023年11月20日公佈了克里斯塔爾生物科技（納斯達克股票代碼：KRYS）的最新目標股價。該分析公司將目標股價定爲160.00美元，預計KRYS將在12個月內升至12個月內（可能上漲53.61％）。去年有22家分析公司公佈了評級。
What is the most recent analyst rating for Krystal Biotech (KRYS)?
分析師對Krystal Biotech（KRYS）的最新評級是多少？
The latest analyst rating for Krystal Biotech (NASDAQ: KRYS) was provided by Goldman Sachs, and Krystal Biotech initiated their buy rating.
高盛提供了Krystal Biotech（納斯達克股票代碼：KRYS）的最新分析師評級，Krystal Biotech啓動了買入評級。
When is the next analyst rating going to be posted or updated for Krystal Biotech (KRYS)?
Krystal Biotech（KRYS）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Krystal Biotech的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Krystal Biotech的最新評級是在2023年11月20日發佈的，因此您應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating Krystal Biotech (KRYS) correct?
分析師對克里斯塔爾生物科技（KRYS）的評級是否正確？
While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a initiated with a price target of $0.00 to $160.00. The current price Krystal Biotech (KRYS) is trading at is $104.16, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Krystal Biotech（KRYS）評級是啓動的，目標股價爲0.00美元至160.00美元。克里斯塔爾生物科技（KRYS）目前的交易價格爲104.16美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。